Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 41, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2021.116212
Keywords
Asthma; Chronic obstructive pulmonary diseases; Drug synthesis
Ask authors/readers for more resources
Respiratory infections caused by pulmonary inflammation are a leading cause of death worldwide, yet only twenty-seven new drugs have been approved in the past fifty years. This review outlines synthetic approaches and mode of action for these FDA-approved medications used to treat asthma and COPD.
Respiratory infections resulting from pulmonary inflammation emerging as a leading cause of death worldwide. However, only twenty-seven new drugs were approved in the last five decades. In this review, we presented synthetic approaches for twenty-seven FDA-approved medications used to treat asthma and chronic obstructive pulmonary diseases (COPD), along with their mode of action.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available